Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
In a recent study posted to the bioRxiv* preprint server, researchers describe a mucosal vector vaccine for targeting dendritic cells. Study: A synthetic delivery vector for mucosal vaccination. Image ...
Versant Ventures has committed $30 million to improve gene delivery. By pumping the cash into Vector BioPharma, the VC is aiming to address the limitations of existing systems such as the cap on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results